Body fluid MMP-2 as a putative biomarker in metastatic breast cancer

Noh,Sewon; Jung,Jae-Joon; Jung,Minkyu; Kim,Ki-Hyang; Lee,Ha‑Young; Wang,Brandon; Cho,Joanna; Kim,Tae Soo; Jeung,Hei‑Cheul; Rha,Sun Young

doi:10.3892/ol.2012.549

Body fluid MMP-2 as a putative biomarker in metastatic breast cancer

Authors:
- Sewon Noh
- Jae-Joon Jung
- Minkyu Jung
- Ki-Hyang Kim
- Ha‑Young Lee
- Brandon Wang
- Joanna Cho
- Tae Soo Kim
- Hei‑Cheul Jeung
- Sun Young Rha
View Affiliations

Affiliations: Cancer Metastasis Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
Published online on: January 3, 2012 https://doi.org/10.3892/ol.2012.549
Pages: 699-703

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we investigated the role of matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers in the body fluid of patients with metastatic breast cancer. We measured the expression of MMPs in 37 samples of body fluid (10 peritoneal and 27 pleural fluids) from metastatic breast cancer patients between 2000 and 2009. Zymography and ELISA assays were used to determine the cut-off level and to quantify MMP expression from a positive control, HT-1080 conditioned media. MMP expression in patient samples was measured with ELISA and compared with other clinical parameters. Ascitic carcinoembryonic antigen (CEA) and pleural CEA were measured in patient samples with a chemiluminescent enzyme immunoassay. Body fluid cytology had a positivity of 45% (9/20) for pleural fluid and 28.6% (2/7) for ascites. However, MMP-2 had a positivity of 85.2% (23/27) in 27 pleural fluid samples and 100% (10/10) in ascitic fluid with cut-off levels of 8.6 and 0.14 ng/ml for MMP-2 and -9, respectively. When body fluid CEA and MMP-2 were combined, the positivity improved to 96% in pleural fluid and 100% in ascites. MMP-2 expression in body fluid did not show any significant differences, but MMP-9 expression was lower in ascites than in pleural fluids (p<0.005). Our results suggest that MMP-2 expression in body fluid be used as an additive diagnostic marker for metastatic breast cancer patients.

View Figures

View References

1	Tyczynski JE, Plesko I, Aareleid T, et al: Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. Int J Cancer. 112:1056–1064. 2004. View Article : Google Scholar : PubMed/NCBI
2	Holmes MD, Chen WY, Hankinson SE and Willett WC: Physical activity’s impact on the association of fat and fiber intake with survival after breast cancer. Am J Epidemiol. 170:1250–1256. 2009.
3	Jung KW, Won YJ, Park S, et al: Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci. 24:995–1003. 2009. View Article : Google Scholar : PubMed/NCBI
4	Runyon BA, Hoefs JC and Morgan TR: Ascitic fluid analysis in malignancy-related ascites. Hepatology. 8:1104–1109. 1988. View Article : Google Scholar : PubMed/NCBI
5	Abe S, Yoshimura H, Tabara H, et al: Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome. J Surg Oncol. 59:226–229. 1995. View Article : Google Scholar : PubMed/NCBI
6	Terracciano D, Di Carlo A, Papa P, et al: New approaches in the diagnostic procedure of malignant pleural effusions. Oncol Rep. 12:79–83. 2004.PubMed/NCBI
7	Jung M, Jeung HC, Lee SS, et al: The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol. 136:517–526. 2010. View Article : Google Scholar : PubMed/NCBI
8	Gaspar MJ, Arribas I, Coca MC and Diez-Alonso M: Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 22:318–322. 2001. View Article : Google Scholar : PubMed/NCBI
9	de Manzoni G, Verlato G, Di Leo A, et al: Peritoneal cytology does not increase the prognostic information provided by TNM in gastric cancer. World J Surg. 30:579–584. 2006.
10	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
11	Duffy MJ, Maguire TM, Hill A, McDermott E and O’Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:252–257. 2000. View Article : Google Scholar : PubMed/NCBI
12	Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 36:1621–1630. 2000. View Article : Google Scholar : PubMed/NCBI
13	Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15:RA32–40. 2009.PubMed/NCBI
14	Dragutinovic V, Izrael-Zivkovic L and Radovanovic N: Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci. 54:1203–1207. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yajima K, Kanda T, Ohashi M, et al: Clinical and diagnostic significance of preoperative computed tomography findings of ascites in patients with advanced gastric cancer. Am J Surg. 192:185–190. 2006. View Article : Google Scholar : PubMed/NCBI
16	Noh S, Jung JJ, Jung M, et al: MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology. 58:2011.(Epub ahead of print).
17	Lengyel E, Schmalfeldt B, Konik E, et al: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 82:291–298. 2001. View Article : Google Scholar : PubMed/NCBI
18	Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.PubMed/NCBI
19	Lombard C, Saulnier J and Wallach J: Assays of matrix metalloproteinases (MMPs) activities: a review. Biochimie. 87:265–272. 2005. View Article : Google Scholar : PubMed/NCBI
20	Shah FD, Shukla SN, Shah PM, Shukla HK and Patel PS: Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 46:194–202. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hong MK, Cho KY, Oh SJ, Kim KM, Yu SJ and Jung SS: Implications of the Activation of Matrix Metalloproteinase-2 (MMP-2) on the Metastasis in Breast Cancer. J Korean Breast Cancer Soc. 5:19–26. 2002. View Article : Google Scholar
22	Sun XM, Dong WG, Yu BP, Luo HS and Yu JP: Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol. 9:2592–2595. 2003.PubMed/NCBI
23	McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
24	Belotti D, Paganoni P, Manenti L, et al: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 63:5224–5229. 2003.
25	Warren M: Metastatic breast cancer recurrence: a literature review of themes and issues arising from diagnosis. Int J Palliat Nurs. 15:222–225. 2009. View Article : Google Scholar : PubMed/NCBI